Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

F
1018
Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Pathogenesis of CLL

Favorite
2002
Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Clinical Challenges in CLL

Favorite
1206
First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Clinical Challenges in CLL

Favorite
1022
FOXO4 is required for the promotion of CLL growth and survival
Pathogenesis of CLL

Favorite
1125
Frequent monitoring in chronic lymphocytic leukemia clinical trials: what is the true value?
Clinical Challenges in CLL

Favorite